Thiazolidinedione Therapy for Managing Metabolic Syndrome
Metadata[+] Show full item record
There is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting. (Strength of Recommendation: B, based on a single randomized controlled trial). Effects of TZD therapy on nonglycemic markers of metabolic syndrome are inconsistent compared with the effects of other hypoglycemic medications.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.